image
Healthcare - Medical - Devices - NASDAQ - US
$ 1.19
-7.75 %
$ 2.5 M
Market Cap
-0.06
P/E
1. INTRINSIC VALUE

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications.[ Read More ]

The intrinsic value of one BBLG stock under the base case scenario is HIDDEN Compared to the current market price of 1.19 USD, Bone Biologics Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart BBLG

image
FINANCIALS
0 REVENUE
0.00%
-9.43 M OPERATING INCOME
-157.24%
-8.95 M NET INCOME
-502.76%
-9.56 M OPERATING CASH FLOW
-167.90%
0 INVESTING CASH FLOW
0.00%
5.04 M FINANCING CASH FLOW
13.87%
0 REVENUE
0.00%
-951 K OPERATING INCOME
-17.46%
-941 K NET INCOME
-20.07%
-572 K OPERATING CASH FLOW
36.13%
0 INVESTING CASH FLOW
0.00%
1.81 M FINANCING CASH FLOW
604087.29%
Balance Sheet Decomposition Bone Biologics Corporation
image
Current Assets 3.74 M
Cash & Short-Term Investments 3.03 M
Receivables 0
Other Current Assets 711 K
Non-Current Assets 0
Long-Term Investments 0
PP&E 0
Other Non-Current Assets 0
Current Liabilities 831 K
Accounts Payable 361 K
Short-Term Debt 0
Other Current Liabilities 471 K
Non-Current Liabilities 0
Long-Term Debt 0
Other Non-Current Liabilities 0
EFFICIENCY
Earnings Waterfall Bone Biologics Corporation
image
Revenue 0
Cost Of Revenue 0
Gross Profit 0
Operating Expenses 9.43 M
Operating Income -9.43 M
Other Expenses -480 K
Net Income -8.95 M
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-307.90% ROE
-307.90%
-239.41% ROA
-239.41%
-324.40% ROIC
-324.40%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Bone Biologics Corporation
image
Net Income -8.95 M
Depreciation & Amortization 9.43 M
Capital Expenditures 0
Stock-Based Compensation 153 K
Change in Working Capital 133 K
Others -1.02 M
Free Cash Flow -9.56 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Bone Biologics Corporation
image
BBLG has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
86.02% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Bone Biologics Corporation
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
1 year ago
Sep 13, 2023
Bought 5.12 K USD
Walsh Deina H
Chief Financial Officer
+ 8000
0.64 USD
1 year ago
Sep 11, 2023
Bought 6.53 K USD
Frelick Jeff
Chief Executive Officer
+ 9500
0.6874 USD
1 year ago
Sep 06, 2023
Bought 4.76 K USD
Walsh Deina H
Chief Financial Officer
+ 6700
0.71 USD
1 year ago
Sep 06, 2023
Bought 210 USD
Walsh Deina H
Chief Financial Officer
+ 300
0.7 USD
1 year ago
Aug 31, 2023
Bought 5.02 K USD
Frelick Jeff
Chief Executive Officer
+ 7600
0.6605 USD
4 years ago
Jan 02, 2020
Bought 195 K USD
Hankey Bret
Director
+ 195000
1 USD
4 years ago
Jan 02, 2020
Bought 195 K USD
Hankey Don
Chairman of the Board
+ 195000
1 USD
5 years ago
Aug 06, 2019
Bought 0 USD
Hankey Bret
Director
+ 553191
0 USD
5 years ago
Aug 06, 2019
Bought 0 USD
Hankey Don
Chairman of the Board
+ 553191
0 USD
5 years ago
Jul 15, 2019
Bought 0 USD
Hankey Don
Chairman of the Board
+ 85106
0 USD
5 years ago
Jul 15, 2019
Bought 0 USD
Hankey Bret
Director
+ 85106
0 USD
5 years ago
Jun 20, 2019
Bought 0 USD
Hankey Don
Chairman of the Board
+ 1063830
0 USD
5 years ago
Jun 20, 2019
Bought 0 USD
Hankey Bret
Director
+ 1063830
0 USD
5 years ago
May 07, 2019
Bought 0 USD
Hankey Don
Chairman of the Board
+ 1063830
0 USD
5 years ago
May 07, 2019
Bought 0 USD
Hankey Bret
Director
+ 1063830
0 USD
5 years ago
Mar 25, 2019
Bought 0 USD
Hankey Bret
Director
+ 1489362
0 USD
5 years ago
Dec 17, 2018
Bought 0 USD
Hankey Bret
Director
+ 18009696
0 USD
5 years ago
Mar 25, 2019
Bought 0 USD
Hankey Don
Chairman of the Board
+ 1489362
0 USD
5 years ago
Dec 17, 2018
Bought 0 USD
Hankey Don
Chairman of the Board
+ 18009696
0 USD
8 years ago
Dec 22, 2015
Sell 8.33 K USD
SOO B CHIA
Director
- 5274
1.58 USD
8 years ago
Dec 22, 2015
Sell 4.17 K USD
WU BENJAMIN
Director
- 2637
1.58 USD
8 years ago
Feb 29, 2016
Bought 1.5 M USD
MUSCULOSKELETAL TRANSPLANT FOUNDATION, INC.
10 percent owner
+ 731707
2.05 USD
9 years ago
Oct 09, 2015
Sell 41.7 K USD
WU BENJAMIN
Director
- 26372
1.58 USD
9 years ago
Oct 09, 2015
Sell 83.3 K USD
SOO B CHIA
Director
- 52744
1.58 USD
9 years ago
Oct 09, 2015
Sell 41.7 K USD
MUSCULOSKELETAL TRANSPLANT FOUNDATION, INC.
Director
- 26372
1.58 USD
9 years ago
Nov 20, 2015
Sell 12.5 K USD
AFH Holding & Advisory, LLC
10 percent owner
- 7911
1.58 USD
9 years ago
Oct 09, 2015
Sell 125 K USD
AFH Holding & Advisory, LLC
10 percent owner
- 79110
1.58 USD
10 years ago
Sep 18, 2014
Sell 50 K USD
AFH Holding & Advisory, LLC
10 percent owner
- 100000
0.5 USD
10 years ago
Sep 18, 2014
Sell 900 USD
AFH Holding & Advisory, LLC
10 percent owner
- 100000
0.009 USD
10 years ago
Sep 18, 2014
Sell 225 USD
AFH Holding & Advisory, LLC
10 percent owner
- 25000
0.009 USD
10 years ago
Sep 18, 2014
Sell 1.8 K USD
AFH Holding & Advisory, LLC
10 percent owner
- 200000
0.009 USD
7. News
Bone Biologics Announces Exercise of Warrants for $2.1 Million Gross Proceeds BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of 781,251 shares of its common stock having an exercise price of $2.43 per share, originally issued in March 2024. The issuance of the shares of common stock issuable upon exerc. businesswire.com - 3 months ago
First Two Patients Treated in Pilot Clinical Study with Bone Biologics' NB1 Bone Graft Device in Spine Fusion BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that the first two patients have been treated in the multicenter, prospective, randomized pilot clinical study of the Company's NB1 bone graft device. NB1 is NELL-1 protein combined with demineralized bone matrix (DBM) to provide rapid, specific and guided control over bone regeneration. This pilot cli. businesswire.com - 4 months ago
Bone Biologics Announces Closing of $2.0 Million Public Offering BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced the closing of its previously announced public offering of an aggregate of 781,251 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 781,251 shares of common stock, at a public offering price of $2.56 per share (or common stock equivalent in l. businesswire.com - 8 months ago
Bone Biologics Announces Pricing of $2.0 Million Public Offering BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced the pricing of its public offering of an aggregate of 781,251 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 781,251 shares of common stock, at a public offering price of $2.56 per share (or common stock equivalent in lieu thereof) and acco. businesswire.com - 8 months ago
Bone Biologics Reports Progress With NB1 Clinical Program BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, reports progress with advancing its product candidate NB1 into human clinical testing for spinal fusion. Following Human Research Ethics Committee (HREC) approval last year in Australia for the multicenter, prospective, randomized pilot clinical trial, the Company reports that three hospital sites have been engaged to participate in the pilot clinical tr. businesswire.com - 8 months ago
Bone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon to Board of Directors BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced that effective immediately Robert E. Gagnon has been named to the Company's board of directors. Mr. Gagnon fills the seat left by Erick Lucera, who has resigned effective upon Mr. Gagnon's appointment. The number of directors of Bone Biologics remains at four. Mr. Gagnon is currently chief financ. businesswire.com - 10 months ago
Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced that it has received notice from The NASDAQ Stock Market LLC (Nasdaq) informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Bone Biologics is now in compliance with all. businesswire.com - 10 months ago
Bone Biologics Announces 1-for-8 Reverse Stock Split BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced a planned reverse stock split of its shares of common stock at a ratio of 1-for-8. The reverse stock split will take effect as of 12:01 a.m. ET, on Wednesday, December 20, 2023, and shares of Bone Biologics are expected to trade on a post-split basis on Nasdaq under the existing trading symbol, “. businesswire.com - 11 months ago
Bone Biologics Announces Closing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of an aggregate of 1,139,063 of its shares of common stock at a purchase price of $0.64 per share. In a concurrent private placement, the Company also issued and sold unregistered warrants to purchase up to an aggregate of 1,139,063. businesswire.com - 11 months ago
Why Is Bone Biologics (BBLG) Stock Down 38% Today? Bone Biologics (NASDAQ: BBLG ) stock is falling on Friday after the medical device company's shares underwent a major rally the day prior. That rally was caused by heavy trading of BBLG stock. investorplace.com - 1 year ago
Bone Biologics Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,139,063 of its shares of common stock at a purchase price of $0.64 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the company has also agreed to issue and sell unregistered w. businesswire.com - 1 year ago
Why Is Bone Biologics (BBLG) Stock Up 84% Today? Bone Biologics (NASDAQ: BBLG ) stock is rocketing higher despite a lack of news from the medical device company on Thursday. There are no new press releases or filings with the Securities and Exchange Commission that explain why BBLG stock is up today. investorplace.com - 1 year ago
8. Profile Summary

Bone Biologics Corporation BBLG

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 2.5 M
Dividend Yield 86.02%
Description Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.
Contact 2 Burlington Woods Drive, Burlington, MA, 01803 https://www.bonebiologics.com
IPO Date Oct. 13, 2021
Employees 2
Officers Mr. Jeffrey Frelick Chief Executive Officer & President